Vor Biopharma FY2028 EPS Estimate Decreased by HC Wainwright

Vor Biopharma Inc. (NYSE:VOR) – Research analysts at HC Wainwright reduced their FY2028 EPS estimates for Vor Biopharma in a research note issued to investors on Thursday, August 14th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn $0.03 per share for the year, down from their previous estimate of $0.05. HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for Vor Biopharma’s current full-year earnings is ($1.42) per share. HC Wainwright also issued estimates for Vor Biopharma’s FY2029 earnings at $0.21 EPS.

Other research analysts also recently issued reports about the stock. Wedbush reiterated an “outperform” rating on shares of Vor Biopharma in a research note on Thursday, June 26th. Jones Trading downgraded shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 8th. JMP Securities reiterated a “market perform” rating and set a $6.00 price objective on shares of Vor Biopharma in a research note on Friday, May 9th. Baird R W downgraded shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 8th. Finally, Citizens Jmp downgraded shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 9th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $6.07.

Vor Biopharma Trading Up 8.1%

Shares of VOR stock opened at $2.14 on Friday. The company has a market capitalization of $271.01 million, a PE ratio of -1.30 and a beta of 2.06. The firm has a fifty day simple moving average of $1.59 and a 200-day simple moving average of $1.04. Vor Biopharma has a twelve month low of $0.13 and a twelve month high of $3.29.

Institutional Trading of Vor Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of the business. Northern Trust Corp increased its holdings in shares of Vor Biopharma by 39.0% in the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock worth $175,000 after acquiring an additional 44,252 shares during the period. RA Capital Management L.P. increased its holdings in shares of Vor Biopharma by 74.3% in the 4th quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company’s stock worth $44,007,000 after acquiring an additional 16,897,159 shares during the period. Lynx1 Capital Management LP acquired a new stake in shares of Vor Biopharma in the 4th quarter worth about $707,000. Money Concepts Capital Corp increased its holdings in shares of Vor Biopharma by 106.1% in the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock worth $37,000 after acquiring an additional 26,535 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of Vor Biopharma in the 4th quarter worth about $80,000. 97.29% of the stock is owned by institutional investors and hedge funds.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.